Risk of stent failure in patients with diabetes treated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors: A nationwide observational study
Incretins are a group of glucose-lowering drugs with favourable cardiovascular (CV) effects against neoatherosclerosis. Incretins' potential effect in stent failure is unknown. The aim of this study is to determine if incretin treatment decreases the risk of stent-thrombosis (ST), and/or in-stent restenosis (ISR) after percutaneous coronary intervention (PCI) with implanted drug-eluting stents (DES).
Source: International Journal of Cardiology - Category: Cardiology Authors: Irene Santos-Pardo, Bo Lagerqvist, Viveca Ritsinger, Nils Witt, Anna Norhammar, Thomas Nystr öm Source Type: research
More News: Angioplasty | Cardiology | Cardiovascular | Coronary Angioplasty | Diabetes | Endocrinology | Heart | Incretin Therapy | Percutaneous Coronary Intervention | Study | Thrombosis